drugset / Trial / NCT05936138
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3502970 will also be evaluated in these participants. The study will last up to 6 weeks including screening period.
Timeline
- Start
- 2023-07-13
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orforglipron | Small molecule | 1 mg | Oral |